These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23595360)

  • 21. Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate.
    Kesisoglou F
    AAPS PharmSciTech; 2014 Feb; 15(1):20-28. PubMed ID: 24022346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
    Good DJ; Hartley R; Mathias N; Crison J; Tirucherai G; Timmins P; Hussain M; Haddadin R; Koo O; Nikfar F; Fung NK
    Mol Pharm; 2015 Dec; 12(12):4434-44. PubMed ID: 26536519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process.
    Tiller PR; Romanyshyn LA
    Rapid Commun Mass Spectrom; 2002; 16(12):1225-31. PubMed ID: 12112275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic analysis of modified-release metoprolol formulations: An interspecies comparison.
    De Thaye E; Vervaeck A; Marostica E; Remon JP; Van Bocxlaer J; Vervaet C; Vermeulen A
    Eur J Pharm Sci; 2017 Jan; 97():135-142. PubMed ID: 27816630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
    Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
    Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
    Tolbert JA; Bai S; Abdel-Rahman SM; August KJ; Weir SJ; Kearns GL; Neville KA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28295989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers.
    Chik Z; Basu RC; Pendek R; Lee TC; Mohamed Z
    Clin Ther; 2010 Sep; 32(10):1822-31. PubMed ID: 21194606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrostomy tube placement via a laparotomic procedure in growing conventional piglets to perform multi-dose preclinical paediatric drug studies.
    Millecam J; van Bergen T; Devreese M; Schauvliege S; Martens A; Chiers K; Croubels S; Antonissen G
    Lab Anim; 2020 Jun; 54(3):261-271. PubMed ID: 31242071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers.
    Génissel P; Chodjania Y; Demolis JL; Ragueneau I; Jaillon P
    Eur J Drug Metab Pharmacokinet; 2004; 29(1):61-8. PubMed ID: 15151172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.
    Ostenfeld T; Beaumont C; Bullman J; Beaumont M; Jeffrey P
    Br J Clin Pharmacol; 2012 Dec; 74(6):1033-44. PubMed ID: 22497298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A physiologically based pharmacokinetic model of rifampin in mice.
    Lyons MA; Reisfeld B; Yang RS; Lenaerts AJ
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1763-71. PubMed ID: 23357766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
    Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
    Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs].
    Kaltenbach G; Levêque D; Peter JD; Salmon J; Elkhaili H; Cavalier A; Salmon Y; Monteil H; Jehl F
    Pathol Biol (Paris); 1996 May; 44(5):379-83. PubMed ID: 8758480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.